

Investor Corporate Presentation | August 2026

The Industrial Plant Cell Culture Company

NASDAQ: BHST



Forward Looking Statements

Cautionary Note Regarding Forward-Looking Statements

This presentation contains "forward-looking statements." The statements contained in this presentation that are not purely historical are forward-looking statements. Forward-looking statements give the Company's current expectations or forecasts of future events. Such statements are subject to risks and uncertainties that are often difficult to predict and beyond the control of BioHarvest Sciences, Inc. (the "Company") and could cause the Company's results to differ materially from those described. In some cases, forward-looking statements can be identified by terminology such as "may," "should," "potential," "continue," "expects," "anticipates," "intends," "plans," "believes," "estimates," and similar expressions. These statements include statements regarding moving forward with executing the Company's global growth strategy. Although the company believes it has identified a path to profitability there is no assurance that profitability will be achieved as many factors beyond the control of the company could impact its potential for profitability such as changes in consumer preferences, increases in costs and changes in government regulation. The statements are based upon current beliefs, expectations and assumptions and are subject to a number of risks and uncertainties, many of which are difficult to predict. The Company is providing this information as of the date of this presentation and does not undertake any obligation to update any forward-looking statements contained in this presentation as a result of new information, future events or otherwise, except as required by law. We have based these forward-looking statements largely on our current expectations and projections about future events and financial trends affecting the financial condition of our business. Forward-looking statements should not be read as a guarantee of future performance or results and will not necessarily be accurate indications of the times at, or by, which such performance or results will be achieved.

Non-GAAP or non IFRS Financial Measures

This presentation includes certain financial measures not prepared in accordance with generally accepted accounting principles ("GAAP") and international financial reporting standards ("IFRS"), including Adjusted EBITDA. These non-GAAP and non-IFRS financial measures are not measures of financial performance in accordance with GAAP and IFRS and may exclude items that are significant in understanding and assessing our financial results. Therefore, these measures should not be considered in isolation or as an alternative to measures prepared in accordance with GAAP or IFRS. In addition, our presentation of these measures may not be comparable to similarly-titled financial measures used by other companies. We believe that these non-GAAP and non-IFRS measures, when viewed with our results under GAAP and IFRS and the accompanying reconciliations, provides useful information about our period-over-period results. These non-GAAP and non-IFRS measures are presented because we believe they provide additional information with respect to the performance of our fundamental business activities and are also frequently used by securities analysts, investors and other interested parties in the evaluation of comparable companies. These non-GAAP and non-IFRS financial measures are subject to inherent limitations as they reflect the exercise of judgments by management in determining these non-GAAP and non-IFRS financial measures.

Market & Industry Data

This presentation also contains estimates and other statistical data made by independent parties and by the Company relating to market size and growth and other industry data. This data involves several assumptions and limitations, and you are cautioned not to give undue weight to such estimates. The Company has not independently verified the statistical and other industry data generated by independent parties and contained in this presentation and, accordingly, it cannot guarantee their accuracy or completeness. In addition, projections, assumptions and estimates of its future performance and the future performance of the industries in which it operates are necessarily subject to a high degree of uncertainty and risk due to a variety of factors. These and other factors could cause results to differ materially from those expressed in the estimates made by independent parties and by the Company. For more information, please refer to risk factors discussed in Company's periodic filings with the SEC.

We have filed a registration statement on Form S-3 (No. 333-[289908](#)) with the SEC for the offering to which this presentation relates. Before you invest, you should read the prospectus in that registration statement and other documents we have filed with the SEC for more complete information about BioHarvest and this offering. You may get these documents for free by visiting the SEC website at <http://www.sec.gov>.

This presentation shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

Leadership Team



DR. ZAKI RAKIB

CEO & Executive Chairman

30+ years experience developing disruptive technologies



DR. YOCHI HAGAY

Co-Founder & Chief Technology Officer

20+ years experience in the pharmaceutical & biotech space



DR. ILANA BELZER

Chief Operating Officer

Extensive experience overseeing biotech companies



JARED TURNER

Chief Sales Officer

20+ years experience in managing e-commerce brands systems & marketing



BAR DICHTER

Chief Financial Officer

8+ years experience leading BioHarvest finance team



ILAN SOBEL

Co-Founder, Senior Advisor, Previous CEO & Current Board Member

25+ years developing & executing strategic growth strategies



NEDIRA SALZMAN FRENKEL

VP, Business Development

12+ years experience in business development in biotech sector



BioHarvest At-a-Glance

We are the global leader in plant cell biology



We are able to scale plant cell cultures rapidly AND precisely.

Our proprietary platform allows us to do this from the blueprint of just one plant, preventing us from needing the footprint or capital to grow many plants.

Our focus is the nutraceutical, cosmetic, pharma and nutrition sectors.

4 PARTNERSHIPS



TATE & LYLE



Undisclosed, UAE-backed
fragrance partner

Strategic PDMO

(partner development and
manufacturing organization)

\$35M

2025 Revenue

\$100M

Cumulative Sales

15

patents

Investment Summary

Optimized Business Model

Two sources of value-creation; D2C provides immediate growth support

Industrial Manufacturing Infrastructure

\$5M CapEx historical facility ROI reference; certainty of supply chain unencumbered with stops and starts

Platform Optionality: Four Development Programs Across Four Industries

A diversified pipeline designed to create development, manufacturing and royalty economics.

AI-Enabled Discovery and Scale-up


Computer vision, predictive modeling and in-silico libraries to increase throughput.

2026 guidance: \$37-40M total revenue

D2C: \$33-35M; CDMO: \$4-5M, excluding internal VINIA transfers.

D2C Business Moving Towards Profitability

Driven by VINIA sales to new customer channels




North Star of BHST

To
Discover, Develop,
Manufacture & Democratize
Life-Changing Compounds
From Plants

That Change The World Of Health &
Wellness For Hundreds Of Millions Of
People While Preserving The Planet
For Generations To Come


Natural-Based Molecules: A Fast-Growing Market Opportunity




BIOHARVEST SCIENCES

Nature is NOT an Industrial Supply Chain

The bottleneck is not demand, it is reliable supply




Industrial Biology Platform for Plant-Derived Innovation



Botanical Synthesis™

Programmable plant cell biology generating precision botanics



From nature's biological potential to a reliable industrial supply chain

Technology Benefits



Scalable, predictable and sustainable

one plant yields supply chain certainty
and unlimited production



Lower COGs

compared to extraction
and non-GMO



Ultra-potent molecules

and enhanced efficacy
via elicitation methods



Superior bioavailability

beyond natural
limitations



Controlled consistency,

purity,
reproducibility



Patent-protected

compositions impossible
in nature

AI Driven-Development

Predictive models reduce scale-up and error

Computer vision monitors cell culture in real time

Multi-sensor data fusion optimizes yield and consistency

In-silico library matches molecules to target use-cases

AI-supported discovery expands the CDMO pipeline

AI accelerates biology. Biology still wins.



Product Development Pipeline

High-value Proprietary Assets Create Multiple Pathways For Future Revenue Generation Through Strategic Partnerships, Commercialization, & Licensing Opportunities



Piceid Resveratrol Verbascoside PGG Polyphenol Complex Aromatic Molecule Complex Protein Molecule Safranal, Picro-Crocin, Crocin

Increase in Concentration
of Key Molecule vs Plant Levels

100X

15X

10X

TARGET >1

Chemical Capability
Developed

Complex Polyphenols

Sesquiterpenes
Chromones

Complex
Proteins

Caratenoids

BioHarvest Molecule
Ownership

100%

100%

100%

20%

N/A

25%

Program Pipeline Commercial and Development Programs

		STAGE 1 [\$.5-\$1M]	STAGE 2 [~\$1M]	STAGE 3 [~1M]	INDUSTRIAL & COMMERCIAL VIABILITY
VINIA®					Over \$100 Million in Revenues
Olive Cell Compound					Final Molecule Ready for Production
Fragrance CDMO Client Completed Stage 1 March 2026					Q2 2026 – Stage 2 contract, Stage 3 production secured
Nasdaq-listed Pharma CDMO Client				Milestone Advancement of CDMO Client to Stage 2 Achieved in Q1 2025	
Nutraceuticals CDMO Client Announced October 2025				Q2 2026 – Announced completion of Stage 1 Saffron development	
Nutrition & Sweetener CDMO Client			Q2 2026 - Announced second sweetener molecule added to development partnership		

Pipeline as of August 2026



VINIA® D2C Business Shows The Power Of Our Proprietary Compounds & Ability To Manufacture At Scale

MARKET LEADER · U.S.A.

INTRODUCING THE #1 BLOOD FLOW RESVERATROL BRAND IN THE U.S.

Clinically proven to increase arterial dilation.

#1

Blood Flow Resveratrol Polyphenol brand in the U.S. - based on estimated market size using Nielsen IQ 2025 projections and Amazon sales data.

~95,000+

active D2C users reached for the brand in the U.S. & Israel as of July 2026.


>\$100M

of VINIA® products sold since entering the U.S. market in 2021.

x100

Increase in Piceid Resveratrol versus the plant

Clinically Proven



70% Increase in Arterial Dilation*

Based on our 90-day clinical trial, VINIA® increased arterial dilation by 70%.*



Backed by 17 Years of Science and Innovation.

\$100M invested in R&D

4 clinical studies

8 scientific publications

14 global patents

The Two-Lens View

One Company viewed through two complimentary value creation engines

D2C PRODUCTS

VINIA commercial franchise

2026 guidance: \$33-\$35M

Subscription-driven D2C model

Brand expansion into hydration, chews and hot beverages

Validates manufacturing, quality and consumer demand

Move D2C toward profitability & disciplined cash generation

CDMO PLATFORM

Strategic partner for plant-derived innovation

2026 guidance: \$4-5M


Development revenue today

Manufacturing revenue and royalties later



Platform optionality across four industries

Increase throughput & position CDMO for rapid scaling

BioHarvest Secures 20 Ton Manufacturing & Supply Agreement for Rare Botanical Luxury Fragrance. Estimated \$20-\$30M Revenue in 2027-2028



SESQUITERPENES



CHROMONES



Unlocking Multiple Opportunities to Take a Leadership Position in the Production of Rare Fragrances using Similar Chemistry Developed

Future molecules based on the same intellectual property BioHarvest has developed for the growth of sesquiterpenes, chromones and apocarotenoids.

MATERIAL	YEARS TO USABLE MATERIAL	WHOLESALE PRICE, US\$ / KG (LOG SCALE)
Orris absolute, 80% irone	6 yrs	70,000
Oud oil, wild premium	decades	50,000
Orris butter, 15% irone	6 yrs	13,000
Saffron, dried stigmas	1–3 yrs	5,000
Sandalwood oil, S. album	15–30 yrs	3,000
Oud oil, plantation	5–8 yrs	2,500
Vetiver oil, Haiti	1.5–2 yrs	500
Frankincense oil	8–10 yrs	250
BioHarvest Cell Culture	~3 weeks	per production batch, once the cell line is established

This column measures establishment time, not harvest frequency: saffron establishes fast but yields one harvest a year in a short autumn window. Prices are mid-points of published wholesale ranges, 2025–26 trade data; the frankincense figure is the least well-evidenced.

CDMO Engine For Growth Across 4 Major Industries



COSMETICS/FRAGRANCES

STATUS

- Completed Stage 1
- Now in Stage 2 with 20 Ton Manufacturing Deal Signed

NUTRACEUTICALS

STATUS

- Completed Stage 1
- Now in Stage 2



MULTI-BILLION \$ OPPORTUNITY



PHARMA & BIOTECH

STATUS

- Completed Stage 1 & Step 1 of Stage 2


NUTRITION & SWEETENERS

STATUS

- 2 Compounds in Advanced Step of Stage 1




Anchored by Dec. 2024 Deal with Tate & Lyle



CDMO Revenue Engine

More simultaneous projects create more chances to reach manufacturing and royalties



Scaling R&D throughput is central to scaling CDMO value creation.

The Inflection Point : From Validation to Acceleration

1



D2C scale

VINIA has become a meaningful commercial franchise with >\$100M cumulative sales.

2



CDMO proof

Four third-party programs are advancing simultaneously across four verticals.

3



Manufacturing base

The same infrastructure that enabled VINIA becomes a platform asset.

4



AI + data

Years of process data support discovery, scale-up, and consistency.

Integrated Industrial Infrastructure

R&D, scale-up and production under one operating platform



20–25 tons

current annual
production capacity

75+ tons

expansion
path

\$5M capex

low cost of capital
vs revenue
generated


Israel

deep biotech and
process expertise base


**Our platform scales from boutique
to billion-dollar programs**

Financial Snapshot

D2C revenue (\$M)



CDMO revenue (\$M)
*Includes internal Vinia transfers



Consolidated revenue (\$M)

